Decoding Hepatic Stellate Cell Activation in Liver Fibrosis: Integration of Signaling, Metabolism, and Cellular Heterogeneity for Targeted Therapy
Hepatobiliary Communications · 2026-11 · 100017
DOI: 10.1016/j.hbc.2026.100017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatobiliary Communications, 2026-11. Verfasst von Zilin Ma und 1 weiteren Autor:innen. Die Arbeit nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Hepatic stellate cells (HSCs) are the principal effectors of liver fibrosis. In the healthy liver, HSCs reside in a quiescent state characterized by lipid storage, whereas chronic injury induces their transdifferentiation into activated, myofibroblast-like cells (MFBs). This phenotypic switch arises from the integration of multiple cues, including profibrotic signaling networks, alterations in tissue mechanics, and dynamic metabolic remodeling. Canonical pathways such as transforming growth factor-β (TGF-β), Wnt, and Hedgehog (Hh) converge with inflammatory signaling to reinforce fibrogenic activation and sustain extracellular matrix (ECM) deposition. To meet the increased energetic and biosynthetic demands, activated HSCs (aHSCs) undergo profound metabolic reprogramming, characterized by reorganization of lipid metabolism, accompanied by enhanced glycolysis and increased glutamine utilization. Advances in single-cell and spatially resolved technologies have further uncovered marked heterogeneity among HSC populations, revealing functionally specialized subsets shaped by their zonal localization and microenvironmental context. These mechanistic insights have accelerated the development of therapeutic strategies aimed at selectively targeting HSCs, including pathway-specific inhibitors and emerging delivery platforms such as lipid nanoparticles (LNPs) and exosome-based systems, which enable improved cellular precision. A comprehensive understanding of the interplay between signaling cascades, metabolic adaptation, and microenvironmental regulation provides a critical foundation for the development of next-generation antifibrotic therapies.
Zitieren
APA
Ma, Z., & Cong, M. (2026). Decoding Hepatic Stellate Cell Activation in Liver Fibrosis: Integration of Signaling, Metabolism, and Cellular Heterogeneity for Targeted Therapy. Hepatobiliary Communications, 100017. https://doi.org/10.1016/j.hbc.2026.100017
Vancouver
Ma Z, Cong M. Decoding Hepatic Stellate Cell Activation in Liver Fibrosis: Integration of Signaling, Metabolism, and Cellular Heterogeneity for Targeted Therapy. Hepatobiliary Communications. 2026:100017. doi:10.1016/j.hbc.2026.100017
BibTeX
@article{Ma2026,
author = {Ma, Zilin and Cong, Min},
title = {Decoding Hepatic Stellate Cell Activation in Liver Fibrosis: Integration of Signaling, Metabolism, and Cellular Heterogeneity for Targeted Therapy},
journal = {Hepatobiliary Communications},
year = {2026},
pages = {100017},
doi = {10.1016/j.hbc.2026.100017}
}
EUVIMED